LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-20
Case ID: NM_000051.4_c.6248G_C_20261120_210936
Framework: ACMG/AMP 2015
Variant classification summary

NM_000051.4:c.6248G>C

ATM  · NP_000042.3:p.(Gly2083Ala)  · NM_000051.4
GRCh37: chr11:108188149 G>C  ·  GRCh38: chr11:108317422 G>C
Gene: ATM Transcript: NM_000051.4
Final call
VUS
PP3 supporting BS3 supporting
All criteria require review: For research and educational purposes only.
Gene
ATM
Transcript
NM_000051.4
Protein
NP_000042.3:p.(Gly2083Ala)
gnomAD AF
2.4811094529029602e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
PP3 supporting: SpliceAI maximum delta 0.463 meets the ATM VCEP threshold for predicted splice impact.
2
BS3 supporting: direct prime-editing classified c.6248G>C as Functional with High confidence, indicating functional rescue.
Final determination: Under the ATM VCEP Version 1.6 combining rules, PP3 supporting alone does not satisfy a pathogenic rule and BS3 supporting alone does not satisfy a benign rule; with neither side reaching a rule threshold, the call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.6248G>C is a missense substitution, whereas the VCEP PVS1 rule applies to specified null variants.
cspec vcep_atm_pvs1_1_6
PS1 Not met Not met: no same-amino-acid pathogenic comparator was identified, and SpliceAI max delta 0.463 does not rule out splicing.
vcep_atm_ps1_1_6 cspec PMID:33320972 spliceai
PS2 N/A Not applicable: the ATM VCEP specification explicitly marks PS2 as not applicable.
cspec
PS3 Not met Not met: direct prime-editing classified c.6248G>C as Functional with High confidence, indicating rescue rather than failure of ATM-specific function.
cspec vcep_suppl_tables1_pmid_40580951 PMID:40580951 vcep_clingen_hbop_atm_supplementary_tables_1_and_2_v1
PS4 Not assessed Not assessed: available studies report aggregate ATM missense associations, not variant-specific counts or an odds ratio for c.6248G>C.
cspec PMID:28779002 PMID:33471991 PMID:24418350 PMID:25394175 PMID:20301317 PMID:20301790
PM1 N/A Not applicable: the ATM VCEP prohibits PM1 because benign and pathogenic variants occur in the same domains and hotspots are not well defined.
cspec
PM2 Not met Not met: the highest gnomAD v4.1 subpopulation AF is 0.00160%, above 0.001%, and the variant also occurs in European non-Finnish individuals.
cspec gnomad_v4
PM3 Not assessed Not assessed: no affected-proband, pathogenic-in-trans, phenotype, or phase evidence was available to assign the ATM VCEP's PM3 points.
cspec vcep_atm_pm3_bp2_1_6
PM4 N/A Not applicable: p.(Gly2083Ala) is a missense substitution with no stop-loss consequence, the sole variant type allowed by the VCEP PM4 rule.
cspec
PM5 N/A Not applicable: the ATM VCEP explicitly excludes missense changes from PM5, regardless of same-residue comparator evidence.
cspec
PM6 N/A Not applicable: the ATM VCEP specification explicitly marks PM6 as not applicable.
cspec
PP1 Not assessed Not assessed: no documented affected-relative segregation count or informative meioses is available to meet the VCEP's PP1 thresholds.
cspec
PP2 N/A Not applicable: the ATM VCEP states that ATM lacks a defined low rate of benign missense variation.
cspec
PP3 Met Met: SpliceAI max delta 0.463 meets the ATM VCEP PP3 threshold of >=0.2 for predicted splice impact in missense variants.
cspec spliceai revel vcep_suppl_tables1_pmid_40580951 PMID:40580951
PP4 N/A Not applicable: the ATM VCEP excludes PP4 for hereditary breast cancer and directs ataxia-telangiectasia phenotype evidence into PM3/BP2.
cspec
PP5 N/A Not applicable: the ATM VCEP explicitly prohibits use of PP5.
cspec
BA1 Not met Not met: gnomAD v4.1 grpmax FAF is 6.8e-07 (0.000068%), below the VCEP's >0.5% BA1 threshold.
cspec gnomad_v4
BS1 Not met Not met: gnomAD v4.1 grpmax FAF is 6.8e-07 (0.000068%), below the VCEP's >0.05% BS1 threshold.
cspec gnomad_v4
BS2 N/A Not applicable: the ATM VCEP excludes BS2 because ATM has incomplete penetrance, regardless of healthy-individual or homozygote observations.
cspec
BS3 Met Met at Supporting: direct prime-editing classified c.6248G>C as Functional with High confidence and DeepATM_predicted=No.
cspec vcep_suppl_tables1_pmid_40580951 PMID:40580951 vcep_clingen_hbop_atm_supplementary_tables_1_and_2_v1
BS4 N/A Not applicable: the ATM VCEP specification explicitly marks BS4 as not applicable.
cspec
BP1 N/A Not applicable: missense pathogenic variants are known for ATM, so the ATM VCEP excludes BP1.
cspec
BP2 Not assessed Not assessed: no unaffected-adult observation, pathogenic co-occurring variant, or cis/trans phase evidence was available to assign the ATM VCEP's BP2 points.
cspec vcep_atm_pm3_bp2_1_6
BP3 N/A Not applicable: the VCEP marks BP3 not applicable, and this variant is missense rather than an in-frame deletion or insertion.
cspec
BP4 Not met Not met: REVEL 0.295 exceeds the <=0.249 BP4 cutoff and SpliceAI max delta 0.463 exceeds the <=0.1 no-impact cutoff.
cspec spliceai revel vcep_suppl_tables1_pmid_40580951 PMID:40580951
BP5 N/A Not applicable: the ATM VCEP instructs reviewers not to use BP5 because ATM has low penetrance and frequent pathogenic-variant co-occurrence.
cspec
BP6 N/A Not applicable: the ATM VCEP explicitly prohibits use of BP6.
cspec
BP7 N/A Not applicable: BP7 is limited to synonymous or deep intronic variants, but this variant is missense.
cspec
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.